Maegim한국어

진양제약

007370KOSDAQSector: Pharma & Biotech
₩3,820▲ 2.14%Market cap ₩54.0BAs of Jul 21, 2026 close · updated once daily
B
Grade B64.5 ptsTop 23% of 2,523 stocks
Financial strength
49.2
Growth momentum
42.2
Price attractiveness
97.8

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

49.2
How much debt does it carry relative to equity?
Debt-to-equity ratio
67.5%
✗ Below median · Top 62.8% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
52.3%
✗ Below median · Top 92.1% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
2.1%
✓ Above median · Top 41.4% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
13.9%
✓ Above median · Top 7.1% in sector
Sector median -4.5%

Source filing: annual report (separate) — view original ↗

2

Growth momentum

42.2
How much did revenue grow in a year?
Revenue growth (YoY)
6.5%
✓ Above median · Top 49.5% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
16.5%
✓ Above median · Top 16.8% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
-78.4%
✗ Below median · Top 88.2% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
-77.3%
✗ Below median · Top 76.6% in sector
Sector median 3.5%

Source filing: annual report (separate) — view original ↗

3

Price attractiveness

97.8
Is the price expensive relative to earnings?
P/E (price-to-earnings)
2.4x
✓ Above median · Top 1% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
0.34x
✓ Above median · Top 3.5% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15